Hemogenyx Pharmaceuticals (LSE:HEMO) FCF Yield %: -6.59 (As of Jul. 05, 2026)


LSE:HEMO Hemogenyx Pharmaceuticals PLC LSE:HEMO
31 GF Score
Price £7.70
! 2 Warning Signs
View Full Analysis

What is Hemogenyx Pharmaceuticals FCF Yield %?

Hemogenyx Pharmaceuticals LSE:HEMO +2.67% 31 FCF Yield % is -6.59 as of Jul. 05, 2026. GuruFocus rates LSE:HEMO with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Hemogenyx Pharmaceuticals ranks better than 57.06% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Hemogenyx Pharmaceuticals's Trailing 12-Month Free Cash Flow is £-3.45 Mil, and Market Cap is £52.36 Mil. Therefore, Hemogenyx Pharmaceuticals's FCF Yield % for today is -6.59%.

The historical rank and industry rank for Hemogenyx Pharmaceuticals's FCF Yield % or its related term are showing as below:

LSE:HEMO' s FCF Yield % Range Over the Past 10 Years
Min: -6.59   Med: 0   Max: 0
Current: -6.59

LSE:HEMO's FCF Yield % is ranked better than
57.06% of 1409 companies
in the Biotechnology industry
Industry Median: -9.25 vs LSE:HEMO: -6.59

Hemogenyx Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

Hemogenyx Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Hemogenyx Pharmaceuticals FCF Yield % Related Terms

Hemogenyx Pharmaceuticals FCF Yield % Historical Data

* Premium members only.

The historical data trend for Hemogenyx Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemogenyx Pharmaceuticals FCF Yield % Chart

Hemogenyx Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.76 -25.73 -23.02 -29.26 -9.99

Hemogenyx Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.73 -26.75 -25.21 -107.58 1.94

LSE:HEMO vs VRTX, REGN, ALNY: FCF Yield % Comparison

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's FCF Yield % falls into.


LSE:HEMO
31GF Score
Hemogenyx Pharmaceuticals PLC LSE:HEMO
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemogenyx Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Hemogenyx Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-3.452 / 34.55452
=-9.99%

Hemogenyx Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=0.335 * 2 / 34.55452
=1.94%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -6.59 mean?
Hemogenyx Pharmaceuticals (LSE:HEMO) has a FCF Yield % of -6.59 as of Jul. 05, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Hemogenyx Pharmaceuticals and its competitors. According to the industry distribution chart, Hemogenyx Pharmaceuticals ranks #605 out of 1409 companies in the Biotechnology industry, placing it in the top 42.9%.
Is Hemogenyx Pharmaceuticals' FCF Yield % too high?
Hemogenyx Pharmaceuticals' current FCF Yield % is -6.59. Based on the distribution chart, Hemogenyx Pharmaceuticals ranks #605 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Hemogenyx Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hemogenyx Pharmaceuticals' FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hemogenyx Pharmaceuticals ranks #605 out of 1409 companies for FCF Yield %. This puts Hemogenyx Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Hemogenyx Pharmaceuticals and its competitors. Hemogenyx Pharmaceuticals's current FCF Yield % is -6.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemogenyx Pharmaceuticals stock overvalued right now?
Hemogenyx Pharmaceuticals (LSE:HEMO) has a current FCF Yield % of -6.59. The current FCF Yield % is -6.59. Hemogenyx Pharmaceuticals' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Hemogenyx Pharmaceuticals (LSE:HEMO), the current FCF Yield % is -6.59 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemogenyx Pharmaceuticals Business Description

Address 6 Heddon Street, London, GBR, W1B 4BT
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
31GF Score

Get the complete analysis for LSE:HEMO

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£7.70
Price